JAEA
  • help
  • PC | SP
  • JP | EN
          
Refine your search：     
Report No.
 - 
Clear All
Search Results: Records 1-7 displayed on this page of 7
  • 1

Presentation/Publication Type

Initialising ...

Refine

Journal/Book Title

Initialising ...

Meeting title

Initialising ...

First Author

Initialising ...

Keyword

Initialising ...

Language

Initialising ...

Publication Year

Initialising ...

Held year of conference

Initialising ...

Save select records

Journal Articles

Rational evaluation of the therapeutic effect and dosimetry of auger electrons for radionuclide therapy in a cell culture model

Shinohara, Ayaka*; Hanaoka, Hirofumi*; Sakashita, Tetsuya*; Sato, Tatsuhiko; Yamaguchi, Aiko*; Ishioka, Noriko*; Tsushima, Yoshito*

Annals of Nuclear Medicine, 32(2), p.114 - 122, 2018/02

https://doi.org/10.1007/s12149-017-1225-9
 Times Cited Count：8 Percentile：43.53(Radiology, Nuclear Medicine & Medical Imaging)

Radionuclide therapy with low-energy auger electron emitters could potentially provide high anti-tumor efficacy while keeping normal organs toxicity low. In this study, we evaluated the usefulness of auger electron emitter $$^{125}$$I and compared it with beta-emitter $$^{131}$$I for tumor treatment in 2D and 3D cell culture models. The computer simulation model for 2D and 3D cell culture were constructed, and the absorbed radiation dose of $$^{125}$$I or $$^{131}$$I in each model were calculated by using a Monte Carlo simulation code (PHITS). The therapeutic effect of $$^{125}$$I was comparable to that of $$^{131}$$I in 2D model, but the efficacy was inferior to that of $$^{131}$$I-MIBG in 3D model, since crossfire effect is negligible and the homogeneous distribution of radionuclide was insufficient.

Journal Articles

Monitoring of positron using high-energy gamma camera for proton therapy

Yamamoto, Seiichi*; Toshito, Toshiyuki*; Komori, Masataka*; Morishita, Yuki*; Okumura, Satoshi*; Yamaguchi, Mitsutaka; Saito, Yuichi; Kawachi, Naoki; Fujimaki, Shu

Annals of Nuclear Medicine, 29(3), p.268 - 275, 2015/04

https://doi.org/10.1007/s12149-014-0936-4
 Times Cited Count：21 Percentile：67.44(Radiology, Nuclear Medicine & Medical Imaging)

Journal Articles

Biological evaluation of 3-[$$^{18}$$F]fluoro-$$alpha$$-methyl-D-tyrosine (D-[$$^{18}$$F]FAMT) as a novel amino acid tracer for positron emission tomography

Ohshima, Yasuhiro; Hanaoka, Hirofumi*; Tominaga, Hideyuki*; Kanai, Yoshikatsu*; Kaira, Kyoichi*; Yamaguchi, Aiko*; Nagamori, Shushi*; Oriuchi, Noboru*; Tsushima, Yoshito*; Endo, Keigo*; et al.

Annals of Nuclear Medicine, 27(4), p.314 - 324, 2013/05

https://doi.org/10.1007/s12149-013-0687-7
 Times Cited Count：15 Percentile：49.83(Radiology, Nuclear Medicine & Medical Imaging)

Journal Articles

Bibliometric study of radiation application on microdose useful for new drug development

Komoda, Fumio*; Suzuki, Akiko*; Yanagisawa, Kazuaki; Inoue, Tomio*

Annals of Nuclear Medicine, 23(10), p.829 - 841, 2009/12

https://doi.org/10.1007/s12149-009-0311-z
 Times Cited Count：1 Percentile：7.52(Radiology, Nuclear Medicine & Medical Imaging)

The number of newly approved medicines for market decreased because of the great disparity between animal model in pre-clinical trial and human model in clinical trial. This bottleneck may be expected to be gotten rid of by change in paradigm of drug development based on microdosing, which is enabled by radiation related imaging technology. However, this is impossible without being accompanied by interdisciplinary joint researches, in which clinical investigators belonging to medical schools or hospitals play the most decisive role. In this article, authors verify based on bibliometrics that Japan has not employed the opportunity for revitalizing drug research activities because Japanese researchers' attitude towards radiation technology may not be so positive in comparison with the US, and because the role which clinical investigators play in the phase of pre-clinical trial is smaller in Japan than in the U.S.A..

Journal Articles

Preparation and evaluation of $$^{186/188}$$Re-labeled antibody (A7) for radioimmunotherapy with rhenium(I) tricarbonyl core as a chelate site

Ogawa, Kazuma*; Kawashima, Hidekazu*; Kinuya, Seigo*; Shiba, Kazuhiro*; Onoguchi, Masahisa*; Kimura, Hiroyuki*; Hashimoto, Kazuyuki; Odani, Akira*; Saji, Hideo*

Annals of Nuclear Medicine, 23(10), p.843 - 848, 2009/12

https://doi.org/10.1007/s12149-009-0319-4
 Times Cited Count：9 Percentile：31.33(Radiology, Nuclear Medicine & Medical Imaging)

Rhenium is one of the most valuable elements for internal radiotherapy because $$^{186/188}$$Re have favorable physical characteristics. However, there are problems when proteins such as antibodies are used as carriers of $$^{186/188}$$Re. Labeling methods require the complicated processes. Therefore, we planned the preparation by a simple method and evaluation of a stable $$^{186/188}$$Re-labeled antibody. For this purpose, we selected $$^{186/188}$$Re(I) tricarbonyl complex as a chelating site. A7 was used as a model protein. $$^{186/188}$$Re-labeled A7 was prepared by directly reacting a $$^{186/188}$$Re(I) tricarbonyl precursor with A7. $$^{186/188}$$Re-(CO)$$_{3}$$-A7 were prepared with radiochemical yields of 23-28%. After purification, $$^{186/188}$$Re-(CO)$$_{3}$$-A7 showed a radiochemical purity of over 95%. In biodistribution experiments, $$^{186/188}$$Re-labeled A7 showed high uptakes in the tumor.

Journal Articles

Evaluation of $$^{64}$$Cu-labeled DOTA-$$_{rm D}$$-Phe$$^{1}$$-Tyr$$^{3}$$-octreotide ($$^{64}$$Cu-DOTA-TOC) for imaging somatostatin receptor-expressing tumors

Hanaoka, Hirofumi*; Tominaga, Hideyuki*; Yamada, Keiichi*; Paudyal, P.*; Iida, Yasuhiko*; Watanabe, Shigeki; Paudyal, B.*; Higuchi, Tetsuya*; Oriuchi, Noboru*; Endo, Keigo*

Annals of Nuclear Medicine, 23(6), p.559 - 567, 2009/08

https://doi.org/10.1007/s12149-009-0274-0
 Times Cited Count：17 Percentile：48.49(Radiology, Nuclear Medicine & Medical Imaging)

Journal Articles

Experimental radioimmunotherapy with $$^{186}$$Re-MAG3-A7 anti-colorectal cancer monoclonal antibody; Comparison with $$^{131}$$I-counterpart

Kinuya, Seigo*; Yokoyama, Kunihiko*; Kobayashi, Katsutoshi; Motoishi, Shoji; Onoma, Katsuyuki; Watanabe, Naoto*; Shuke, Noriyuki*; Bunko, Hisashi*; Nichigishi, Takatoshi*; Tonami, Norihisa*

Annals of Nuclear Medicine, 15(3), p.199 - 202, 2001/06

https://doi.org/10.1007/BF02987831
 Times Cited Count：9 Percentile：31.12(Radiology, Nuclear Medicine & Medical Imaging)

no abstracts in English

7 (Records 1-7 displayed on this page)
  • 1